Amarin Corp Plc (AMRN)

[MedResCollab]

SocialBoom,

We have actually spent little to no time trying to prove the same Steven Giardino that posted on ihub previously about his views on REDUCE-IT failing and his arguments that were negative on NWBO and their tech is not a member of MRC. We have spent almost all of our energy on the argument itself, including what our research has revealed to us to be the confounded nature of the REDUCE-IT trial, Amarin's frivolous IP covering Vascepa and its uses, and the out of synch risk:reward compared with current market value. It is AMRN longs that are seeking to slide around and look past these arguments that are focusing on who is making the argument. That is of course a very common logical fallacy, that those who want AMRN to "make them rich" unconsciously commit to help enable them to ignore the content of our research.

Regards,
-MRC